Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-Outcomes ISA1 tirzepatide in MASLD
CTR20255052Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing tirzepatide with placebo (2 arms). Primary endpoint: Time to first major adverse liver outcome (MALO) composite endpoint. Started Mar 2026; status: active.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20255052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255052.